SCHEMBL9997195

SCHEMBL9997195

COc1ccc(-c2cc(S(=O)(=O)Nc3ccc(C(=O)O)c(O)c3)cnc2Cl)cc1F

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PFKFB3 Q16875 4/20 0.47
▸ MCL1 Q07820 1/20 0.43
▸ FABP4 P15090 4/20 0.42
▸ FABP5 Q01469 3/20 0.42
▸ ALDH1A1 P00352 3/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ LMNA P02545 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ HSD17B10 Q99714 2/20 0.42
▸ MAPT P10636 1/20 0.42
▸ THRB P10828 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ PKM P14618 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ FABP3 P05413 1/20 0.42
▸ KIT P10721 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9997103 0.86 PFKFB3 (0.49) PFKFB3MCL1FABP4FABP5ALDH1A1
SCHEMBL9997530 0.84 PFKFB3 (0.49) PFKFB3MCL1FABP4ALDH1A1LMNA
SCHEMBL9997354 0.83 PFKFB3 (0.49) PFKFB3MCL1FABP4ALDH1A1MEN1
SCHEMBL9997104 0.83 PFKFB3 (0.63) PFKFB3MCL1ALDH1A1MEN1KMT2A
SCHEMBL15055045 0.81 SIRT6 (0.43) PFKFB3FABP4FABP5ALDH1A1MEN1
SCHEMBL9997499 0.81 PFKFB3 (0.55) PFKFB3MCL1ALDH1A1LMNAHSD17B10
SCHEMBL9997078 0.81 PFKFB3 (0.55) PFKFB3MCL1FABP4FABP5ALDH1A1
SCHEMBL9997958 0.81 PFKFB3 (0.63) PFKFB3MCL1FABP4ALDH1A1HSD17B10
SCHEMBL9996852 0.80 PFKFB3 (0.64) PFKFB3MCL1FABP4FABP5ALDH1A1
SCHEMBL9997146 0.80 PFKFB3 (0.46) PFKFB3MCL1ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011161201-A1 BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2011-12-29 — — WO claimed
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES GERO PTE. LTD. (SG) 2023-02-16 — — US disclosed
CN-113396145-A PFKFB3 inhibitors and uses thereof 盖罗发现有限责任公司 2021-09-14 — — CN disclosed
WO-2020080979-A1 PFKFB3 INHIBITORS AND THEIR USES GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) 2020-04-23 — — WO disclosed
WO-2011161201-A1 BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2011-12-29 — — WO disclosed
WO-2011161201-A1 BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2011-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES PFKFB3, PFKFB4, PFKFB1 PFKFB3 1/4885MCL1 1411/4885FABP4 871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback